The signature could be used for prognosis prediction in patients with BLCA and could facilitate decisions regarding whether a patient might respond to BLCA immunotherapy and ADCs targeting Nectin‐4 and HER‐2. Here, ERBB2 is linked to bladder transitional cell carcinoma.